View of 1197 – OPERA-02: a phase 3, randomized, doubleblind, active-controlled study of palazestrant with ribociclib versus letrozole with ribociclib for the first-line treatment of ER+, HER2– advanced breast cancer

Return to Article Details 1197 – OPERA-02: a phase 3, randomized, doubleblind, active-controlled study of palazestrant with ribociclib versus letrozole with ribociclib for the first-line treatment of ER+, HER2– advanced breast cancer Download Download PDF